120 related articles for article (PubMed ID: 34270985)
1. Inhibition of autophagy by YC-1 promotes gefitinib induced apoptosis by targeting FOXO1 in gefitinib-resistant NSCLC cells.
Hu H; Zhang XW; Li L; Hu MN; Hu WQ; Zhang JY; Miao XK; Yang WL; Mou LY
Eur J Pharmacol; 2021 Oct; 908():174346. PubMed ID: 34270985
[TBL] [Abstract][Full Text] [Related]
2. YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1α and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells.
Hu H; Miao XK; Li JY; Zhang XW; Xu JJ; Zhang JY; Zhou TX; Hu MN; Yang WL; Mou LY
Eur J Pharmacol; 2020 May; 874():172961. PubMed ID: 32044322
[TBL] [Abstract][Full Text] [Related]
3. Repurposing loperamide to overcome gefitinib resistance by triggering apoptosis independent of autophagy induction in KRAS mutant NSCLC cells.
Tong CWS; Wu MMX; Yan VW; Cho WCS; To KKW
Cancer Treat Res Commun; 2020; 25():100229. PubMed ID: 33152554
[TBL] [Abstract][Full Text] [Related]
4. Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.
Meng S; Wang G; Lu Y; Fan Z
Lung Cancer; 2018 Jul; 121():82-90. PubMed ID: 29858032
[TBL] [Abstract][Full Text] [Related]
5. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
Costa DB; Halmos B; Kumar A; Schumer ST; Huberman MS; Boggon TJ; Tenen DG; Kobayashi S
PLoS Med; 2007 Oct; 4(10):1669-79; discussion 1680. PubMed ID: 17973572
[TBL] [Abstract][Full Text] [Related]
6. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
Zhao R; Zhou S; Xia B; Zhang CY; Hai P; Zhe H; Wang YY
BMC Cancer; 2016 Jul; 16():491. PubMed ID: 27431492
[TBL] [Abstract][Full Text] [Related]
7. EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.
Han W; Pan H; Chen Y; Sun J; Wang Y; Li J; Ge W; Feng L; Lin X; Wang X; Wang X; Jin H
PLoS One; 2011; 6(6):e18691. PubMed ID: 21655094
[TBL] [Abstract][Full Text] [Related]
8. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
[TBL] [Abstract][Full Text] [Related]
9. Nrf2 but not autophagy inhibition is associated with the survival of wild-type epidermal growth factor receptor non-small cell lung cancer cells.
Zhou Y; Li Y; Ni HM; Ding WX; Zhong H
Toxicol Appl Pharmacol; 2016 Nov; 310():140-149. PubMed ID: 27639429
[TBL] [Abstract][Full Text] [Related]
10. Synergistic effects of gefitinib and thalidomide treatment on EGFR-TKI-sensitive and -resistant NSCLC.
Xia X; Liu Y; Liao Y; Guo Z; Huang C; Zhang F; Jiang L; Wang X; Liu J; Huang H
Eur J Pharmacol; 2019 Aug; 856():172409. PubMed ID: 31132355
[TBL] [Abstract][Full Text] [Related]
11. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
[TBL] [Abstract][Full Text] [Related]
12. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W
Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264
[TBL] [Abstract][Full Text] [Related]
14. Licochalcone B inhibits growth and induces apoptosis of human non-small-cell lung cancer cells by dual targeting of EGFR and MET.
Oh HN; Lee MH; Kim E; Yoon G; Chae JI; Shim JH
Phytomedicine; 2019 Oct; 63():153014. PubMed ID: 31323446
[TBL] [Abstract][Full Text] [Related]
15. Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.
Tang MC; Wu MY; Hwang MH; Chang YT; Huang HJ; Lin AM; Yang JC
PLoS One; 2015; 10(3):e0119135. PubMed ID: 25807554
[TBL] [Abstract][Full Text] [Related]
16. miR-762 activation confers acquired resistance to gefitinib in non-small cell lung cancer.
Ge P; Cao L; Chen X; Jing R; Yue W
BMC Cancer; 2019 Dec; 19(1):1203. PubMed ID: 31823748
[TBL] [Abstract][Full Text] [Related]
17. Dual inhibition of EGFR and MET by Echinatin retards cell growth and induces apoptosis of lung cancer cells sensitive or resistant to gefitinib.
Oh HN; Lee MH; Kim E; Kwak AW; Seo JH; Yoon G; Cho SS; Choi JS; Lee SM; Seo KS; Chae JI; Shim JH
Phytother Res; 2020 Feb; 34(2):388-400. PubMed ID: 31698509
[TBL] [Abstract][Full Text] [Related]
18. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
Wang L; Liu J; Liu J; Chen X; Chang M; Li J; Zhou J; Bai C; Song Y
J Cancer Res Clin Oncol; 2019 Apr; 145(4):861-872. PubMed ID: 30661098
[TBL] [Abstract][Full Text] [Related]
19. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
[TBL] [Abstract][Full Text] [Related]
20. Reduced expression of CYLD promotes cell survival and inflammation in gefitinib-treated NSCLC PC-9 cells: Targeting CYLD may be beneficial for acquired resistance to gefitinib therapy.
Yuan Y; Liu L; Wang Y; Liu S
Cell Biol Int; 2020 Sep; 44(9):1911-1918. PubMed ID: 32441799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
